{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T00:17:08Z","timestamp":1791418628848,"version":"4.3.3"},"reference-count":44,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2021,3,28]],"date-time":"2021-03-28T00:00:00Z","timestamp":1616889600000},"content-version":"unspecified","delay-in-days":27,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Division of Rheumatology and Research, Diakonhjemmet Hospital"},{"name":"National Advisory Unit on Rehabilitation in Rheumatology"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["RMD Open"],"accepted":{"date-parts":[[2021,3,5]]},"published-print":{"date-parts":[[2021,3]]},"abstract":"<jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>Gout is often not adequately treated, and we aimed to apply urate lowering treatment (ULT) combined with individual information to achieve target serum urate (sUA) in clinical practice, and to identify predictors of achievement of this sUA target.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Patients with a recent gout flare and sUA &gt;360 \u00b5mol\/L (&gt;6\u2009mg\/dL) were consecutively included in a single-centre study and managed with a treat-to-target approach combining nurse-led information about gout with ULT. All patients were assessed with tight controls at baseline, 1, 2, 3, 6, 9 and 12 months including clinical examination, information on demographics, lifestyle, self-efficacy and beliefs about medicines. The treatment target was sUA &lt;360 \u00b5mol\/L and multivariable logistic regression was used to identify predictors of target attainment with ORs and 95% CIs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of 211 patients (mean age 56.4 years, disease duration 7.8 years, 95% males), 186 completed the 12-month study. Mean sUA levels decreased from baseline mean 500 to 311 \u00b5mol\/L at 12 months with 85.5% achieving the treatment target. Alcohol consumption at least weekly versus less frequently (OR 0.14; 95%\u2009CI 0.04 to 0.55) as well as beliefs in overuse of medicines (OR per unit 0.77; 95\u2009CI 0.62 to 0.94) decreased the chance of reaching the treatment target, while higher self-efficacy for arthritis symptoms (OR 1.49 per 10 units; 95%\u2009CI 1.09 to 2.05) increased the likelihood.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This study shows that target sUA can be achieved with ULT in most patients. Less self-reported alcohol consumption, low beliefs in overuse of medicines and higher self-efficacy are associated with treatment success.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/rmdopen-2021-001628","type":"journal-article","created":{"date-parts":[[2021,3,29]],"date-time":"2021-03-29T11:10:20Z","timestamp":1617016220000},"page":"e001628","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":26,"title":["12-month results from the real-life observational treat-to-target and tight-control therapy NOR-Gout study: achievements of the urate target levels and predictors of obtaining this target"],"prefix":"10.1136","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6881-9552","authenticated-orcid":false,"given":"Till","family":"Uhlig","sequence":"first","affiliation":[{"name":"Rheumatology, Diakonhjemmet Hospital, Oslo, Norway"},{"name":"Institute of Clinical Medicine, University of Oslo, Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars F","family":"Karoliussen","sequence":"additional","affiliation":[{"name":"Rheumatology, Diakonhjemmet Hospital, Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Sexton","sequence":"additional","affiliation":[{"name":"Rheumatology, Diakonhjemmet Hospital, Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tove","family":"Borgen","sequence":"additional","affiliation":[{"name":"Rheumatology, Diakonhjemmet Hospital, Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Espen A","family":"Haavardsholm","sequence":"additional","affiliation":[{"name":"Rheumatology, Diakonhjemmet Hospital, Oslo, Norway"},{"name":"Institute of Clinical Medicine, University of Oslo, Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8441-3093","authenticated-orcid":false,"given":"Tore K","family":"Kvien","sequence":"additional","affiliation":[{"name":"Rheumatology, Diakonhjemmet Hospital, Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7317-8991","authenticated-orcid":false,"given":"Hilde Berner","family":"Hammer","sequence":"additional","affiliation":[{"name":"Rheumatology, Diakonhjemmet Hospital, Oslo, Norway"},{"name":"Institute of Clinical Medicine, University of Oslo, Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2021,3,29]]},"reference":[{"key":"2025090312473770000_7.1.e001628.1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-204463"},{"key":"2025090312473770000_7.1.e001628.2","doi-asserted-by":"publisher","DOI":"10.1002\/art.30520"},{"key":"2025090312473770000_7.1.e001628.3","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1186\/s13075-016-1062-6","article-title":"Incidence and prevalence of gout in Western Sweden","volume":"18","author":"Dehlin","year":"2016","journal-title":"Arthritis Res Ther"},{"key":"2025090312473770000_7.1.e001628.4","doi-asserted-by":"publisher","DOI":"10.1186\/1477-7525-10-117"},{"key":"2025090312473770000_7.1.e001628.5","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/ket265"},{"key":"2025090312473770000_7.1.e001628.6","doi-asserted-by":"publisher","DOI":"10.1186\/ar4281"},{"key":"2025090312473770000_7.1.e001628.7","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1080\/03009742.2017.1405461","article-title":"Burden of gout in the Nordic region, 1990-2015: findings from the global burden of disease study 2015","volume":"47","author":"Kiadaliri","year":"2018","journal-title":"Scand J Rheumatol"},{"key":"2025090312473770000_7.1.e001628.8","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-209707"},{"key":"2025090312473770000_7.1.e001628.9","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-209467"},{"key":"2025090312473770000_7.1.e001628.10","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1002\/art.41247","article-title":"2020 American College of rheumatology guideline for the management of gout","volume":"72","author":"FitzGerald","year":"2020","journal-title":"Arthritis Rheumatol"},{"key":"2025090312473770000_7.1.e001628.11","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-201687"},{"key":"2025090312473770000_7.1.e001628.12","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2014.14484"},{"key":"2025090312473770000_7.1.e001628.13","doi-asserted-by":"publisher","DOI":"10.7326\/M16-0570"},{"key":"2025090312473770000_7.1.e001628.14","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kex421"},{"key":"2025090312473770000_7.1.e001628.15","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kep047"},{"key":"2025090312473770000_7.1.e001628.16","doi-asserted-by":"publisher","DOI":"10.1002\/acr.22469"},{"key":"2025090312473770000_7.1.e001628.17","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/j.semarthrit.2017.09.007","article-title":"Medication adherence among patients with gout: a systematic review and meta-analysis","volume":"47","author":"Scheepers","year":"2018","journal-title":"Semin Arthritis Rheum"},{"key":"2025090312473770000_7.1.e001628.18","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2007.070755"},{"key":"2025090312473770000_7.1.e001628.19","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-201676"},{"key":"2025090312473770000_7.1.e001628.20","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)32158-5"},{"key":"2025090312473770000_7.1.e001628.21","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-203226"},{"key":"2025090312473770000_7.1.e001628.22","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2015-208237"},{"key":"2025090312473770000_7.1.e001628.23","doi-asserted-by":"publisher","DOI":"10.1002\/art.10993"},{"key":"2025090312473770000_7.1.e001628.24","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780230202"},{"key":"2025090312473770000_7.1.e001628.25","doi-asserted-by":"publisher","DOI":"10.1080\/00207411.1994.11449283"},{"key":"2025090312473770000_7.1.e001628.26","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1002\/anr.1780320107","article-title":"Development and evaluation of a scale to measure perceived self-efficacy in people with arthritis","volume":"32","author":"Lorig","year":"1989","journal-title":"Arthritis Care Res."},{"key":"2025090312473770000_7.1.e001628.27","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-3999(99)00057-4"},{"key":"2025090312473770000_7.1.e001628.28","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1002\/acr.23995","article-title":"Comparative study of Real\u2010Life management strategies in gout: data from two Protocolized gout clinics","volume":"72","author":"Kampe","year":"2020","journal-title":"Arthritis Care Res"},{"key":"2025090312473770000_7.1.e001628.29","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.181214"},{"key":"2025090312473770000_7.1.e001628.30","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1093\/rheumatology\/kex521","article-title":"Management of gout by UK rheumatologists: a British Society for rheumatology national audit","volume":"57","author":"Roddy","year":"2018","journal-title":"Rheumatology"},{"key":"2025090312473770000_7.1.e001628.31","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.200113"},{"key":"2025090312473770000_7.1.e001628.32","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1016\/S0140-6736(04)16000-5","article-title":"Alcohol intake and risk of incident gout in men: a prospective study","volume":"363","author":"Choi","year":"2004","journal-title":"The Lancet"},{"key":"2025090312473770000_7.1.e001628.33","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2013.12.019"},{"key":"2025090312473770000_7.1.e001628.34","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1097\/BOR.0b013e3283438e13","article-title":"Risk factors for gout and prevention: a systematic review of the literature","volume":"23","author":"Singh","year":"2011","journal-title":"Curr Opin Rheumatol"},{"key":"2025090312473770000_7.1.e001628.35","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpsychores.2007.07.016"},{"key":"2025090312473770000_7.1.e001628.36","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1111\/ijpp.12353","article-title":"Beliefs about medicines among Hong Kong hospital outpatients","volume":"25","author":"BKF","year":"2017","journal-title":"Int J Pharm Pract"},{"key":"2025090312473770000_7.1.e001628.37","doi-asserted-by":"publisher","DOI":"10.1002\/acr.22336"},{"key":"2025090312473770000_7.1.e001628.38","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1002\/acr.24032","article-title":"Patient and caregiver priorities for medication adherence in gout, osteoporosis, and rheumatoid arthritis: nominal group technique","volume":"72","author":"Kelly","year":"2020","journal-title":"Arthritis Care Res"},{"key":"2025090312473770000_7.1.e001628.39","doi-asserted-by":"crossref","unstructured":"Garcia\u2010Guillen A , Stewart S , Su I , et al . Gout flare severity from the patient perspective: a qualitative interview study. Arthritis Care Res 2020 (published Online First: 2020\/10\/08).doi:10.1002\/acr.24475","DOI":"10.1002\/acr.24475"},{"key":"2025090312473770000_7.1.e001628.40","doi-asserted-by":"publisher","DOI":"10.2337\/dc09-2153"},{"key":"2025090312473770000_7.1.e001628.41","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-217392"},{"key":"2025090312473770000_7.1.e001628.42","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1186\/s13075-019-1976-x","article-title":"Baseline urate level and renal function predict outcomes of urate-lowering therapy using low doses of febuxostat and benzbromarone: a prospective, randomized controlled study in a Chinese primary gout cohort","volume":"21","author":"Liang","year":"2019","journal-title":"Arthritis Res Ther"},{"key":"2025090312473770000_7.1.e001628.43","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1093\/rheumatology\/key237","article-title":"Can we predict inadequate response to allopurinol dose escalation? analysis of a randomised controlled trial","volume":"57","author":"Stamp","year":"2018","journal-title":"Rheumatology"},{"key":"2025090312473770000_7.1.e001628.44","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.190522"}],"container-title":["RMD Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/rmdopen-2021-001628","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T19:47:44Z","timestamp":1756928864000},"score":1,"resource":{"primary":{"URL":"https:\/\/rmdopen.bmj.com\/lookup\/doi\/10.1136\/rmdopen-2021-001628"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3]]},"references-count":44,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,3,29]]},"published-print":{"date-parts":[[2021,3]]}},"alternative-id":["10.1136\/rmdopen-2021-001628"],"URL":"https:\/\/doi.org\/10.1136\/rmdopen-2021-001628","relation":{},"ISSN":["2056-5933"],"issn-type":[{"value":"2056-5933","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3]]}}}